MIRUM PHARMACEUTICALS INC (MIRM) Stock Price, Forecast & Analysis
NASDAQ:MIRM • US6047491013
MIRM Key Statistics, Chart & Performance
The current stock price of MIRM is 102.79 USD. In the past month the price increased by 10.44%. In the past year, price increased by 99.6%.
MIRM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MIRM. When comparing the yearly performance of all stocks, MIRM is one of the better performing stocks in the market, outperforming 94.78% of all stocks.
MIRM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MIRM. While MIRM seems to be doing ok healthwise, there are quite some concerns on its profitability.
MIRM Financial Highlights
Over the last trailing twelve months MIRM reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 57.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| Debt/Equity | 1.06 |
MIRM Forecast & Estimates
16 analysts have analysed MIRM and the average price target is 116.99 USD. This implies a price increase of 13.82% is expected in the next year compared to the current price of 102.79.
For the next year, analysts expect an EPS growth of 85% and a revenue growth 53.97% for MIRM
MIRM Ownership
MIRM Latest News, Press Relases and Analysis
MIRM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.72 | 390.397B | ||
| AMGN | AMGEN INC | 16.43 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.14 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.92 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.04 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.75 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.84 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.18 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MIRM
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 355 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
Company Info
MIRUM PHARMACEUTICALS INC
989 East Hillsdale Boulevard, Suite 300
Foster City CALIFORNIA 94404 US
CEO: Christopher Peetz
Employees: 355
Phone: 13023368212
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What does MIRM do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 355 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
What is the current price of MIRM stock?
The current stock price of MIRM is 102.79 USD. The price increased by 2.91% in the last trading session.
What is the dividend status of MIRUM PHARMACEUTICALS INC?
MIRM does not pay a dividend.
What is the ChartMill technical and fundamental rating of MIRM stock?
MIRM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) currently has 355 employees.
What is the market capitalization of MIRM stock?
MIRUM PHARMACEUTICALS INC (MIRM) has a market capitalization of 5.28B USD. This makes MIRM a Mid Cap stock.
What is the next earnings date for MIRM stock?
MIRUM PHARMACEUTICALS INC (MIRM) will report earnings on 2026-02-24, after the market close.